Form 4: Adicet Bio, Inc. Executive Granted Stock Options
SEC Form 4 Filing
Don Healey, Chief Technology Officer of Adicet Bio, Inc., was granted stock options to purchase 275,000 shares of common stock on January 31, 2025.
Summary
- Don Healey, the Chief Technology Officer of Adicet Bio, Inc. (ACET), was granted stock options on January 31, 2025.
- The options allow Healey to purchase 275,000 shares of Adicet Bio's common stock at an exercise price of $0.885 per share.
- The options vest monthly over a period of 48 months, starting from the grant date, contingent upon Healey's continued service with the company.
- Following the transaction, Healey directly owns derivative securities for 275,000 shares.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a routine part of executive compensation and signals confidence in the executive's future contributions. There are no explicit negative indicators.
Positives
- The granting of stock options aligns the executive's interests with those of the shareholders, incentivizing him to contribute to the company's long-term success.
- The vesting schedule encourages continued service and commitment from the Chief Technology Officer.
Future Outlook
The document does not contain specific forward-looking statements, but the stock option grant suggests an expectation of continued contributions from the executive.
Industry Context
Stock option grants are a common practice in the biotechnology industry to attract and retain key talent, aligning their interests with the company's performance and shareholder value.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry.
- Companies like Amgen, Gilead, and Biogen routinely use stock options to incentivize their executives.
- The size of the grant (275,000 shares) would need to be compared to grants made to CTOs at companies of similar size and stage of development to determine if it is in line with industry norms.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it incentivizes the CTO to work towards increasing shareholder value.
- Employees may see the grant as a sign of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 01/31/2025 | Date of earliest transaction (grant date of stock options) |
| 01/31/2025 | Stock option grant date |
| 01/30/2035 | Stock option expiration date |
| 02/04/2025 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.